Tradestie Institutional Equity Comparison Engine

LMRI vs LBRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LBRX Overall Edge

LBRX Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to LB Pharmaceuticals Inc Common Stock (LBRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LMRI trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus LBRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LMRI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against LBRX sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LMRI N/M vs LBRX N/M Fwd P/E
Growth & Margin Winner LBRX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner LBRX
1Y -23.0% vs +144.7% ยท 52W Pos 60% vs 68%
Options & Structure Winner LBRX
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (4th %ile IV)
LMRI US Equity
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
1M Return +30.95%
1Y Return -23.0%
Forward P/E N/M
Unified AI Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
LBRX NASDAQ
LB Pharmaceuticals Inc Common Stock
Pharmaceutical Preparations
$38.85
-2.97% 1D
Market Cap $1.3B
1M Return -1.45%
1Y Return +144.72%
Forward P/E N/M
Unified AI Score
38.2 / 100 SELL
Tech 20.0 Fund 36.0 Flow 54.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LMRI -23.0% LBRX +144.72% Spread: +115.04 pp (LBRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LMRI TTM Op. Margin: N/A LBRX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LMRI vs LBRX. Trailing 12-month operating profitability (LMRI N/A vs LBRX 0.0%) and valuation multiples (LMRI N/M vs LBRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LMRI (0) vs LBRX (8)
Institutional Metric LMRI LBRX Criterion Row Winner
Market Capitalization Scale N/A $1.3B Larger Scale LBRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth LBRX
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin LBRX
Net Profit Margin Profitability N/A 0.0% Higher Margin LBRX
Return on Equity (ROE) Capital Efficiency N/A -38.8% Higher ROE LBRX
52-Week Range Position Momentum 60% ($6โ€“$19) 68% ($15โ€“$50) Stronger Trend LBRX
Beta / 30D Volatility Risk Regime 1.22ฮฒ ยท 85% Vol 1.07ฮฒ ยท 60% Vol Lower Realized Risk LBRX
Unified Institutional Score Composite Signal 32.1 / 100 (SELL) 38.2 / 100 (SELL) Higher Composite LBRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LMRI vs LBRX Buy Guide
LMRI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LMRI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LBRX CONSOLIDATION
66d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live LBRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LMRI nor LBRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.